

Special Issue

Cancer Vaccines and Immunotherapy: Latest Advances, Limitations and Prospects

Message from the Guest Editors

We invite you to participate in this Special Issue dedicated to the latest advancements and future prospects in cancer vaccines and immunotherapy. This Special Issue aims to enhance our understanding of the potential of cancer vaccines and immunotherapy, as well as their limitations, and provide insights for improving their effectiveness. We welcome original research articles and reviews covering a range of topics, including the latest advances in cancer vaccines and immunotherapy, their impact on the immune system and the response to cancer cells, and their combination with other cancer therapies. We also welcome studies based on the effectiveness of these treatments in cancer management, their potential for preventing cancer recurrence, as well as any potential side effects and risks associated with them. Additionally, we encourage submissions addressing the challenges and limitations of using cancer vaccines and immunotherapy in clinical practice and offering approaches to improve their efficacy and accessibility to cancer patients. We look forward to receiving your valuable contributions to this Special Issue.

Guest Editors

Prof. Dr. Eyad Elkord

1. Department of Biological Sciences, School of Science, Suzhou Municipal Key Lab in Biomedical Sciences and Translational Immunology, Xi'an Jiaotong-Liverpool University, 111 Ren'ai Road, Suzhou Industrial Park, Suzhou 215123, China
2. Biomedical Research Center, School of Science, Engineering and Environment, University of Salford, Manchester, UK
3. College of Health Sciences, Abu Dhabi University, Abu Dhabi, United Arab Emirates

Dr. Afsheen Raza

College of Health Sciences, Abu Dhabi University, Abu Dhabi, United Arab Emirates

Deadline for manuscript submissions

30 November 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/207422

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).